Analytical Data
-
Gene name
MAGEA12
- Application
-
Alternative Names
MAGEA12；MAGE12；Melanoma-associated antigen 12
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P43365
-
Expression Region
1-314aa
-
AA Sequence
MPLEQRSQHCKPEEGLEAQGEALGLVGAQAPATEEQETASSSSTLVEVTLREVPAAESPSPPHSPQGASTLPTTINYTLWSQSDEGSSNEEQEGPSTFPDLETSFQVALSRKMAELVHFLLLKYRAREPFTKAEMLGSVIRNFQDFFPVIFSKASEYLQLVFGIEVVEVVRIGHLYILVTCLGLSYDGLLGDNQIVPKTGLLIIVLAIIAKEGDCAPEEKIWEELSVLEASDGREDSVFAHPRKLLTQDLVQENYLEYRQVPGSDPACYEFLWGPRALVETSYVKVLHHLLKISGGPHISYPPLHEWAFREGEE
-
Molecular Weight
42.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAGEA12 is a member of the melanoma-associated antigen gene family, which plays a crucial role in tumor immune evasion and is primarily expressed in various tumors but not in normal tissues. The study of MAGEA12 recombinant protein is significant as it represents a promising candidate for cancer immunotherapy and vaccine development, particularly in melanoma and other cancers where MAGE antigens are overexpressed. Research on MAGEA12 has focused on understanding its structure, immunogenicity, and potential as a target for therapeutic interventions. The protein's ability to elicit specific immune responses makes it an attractive target for cancer vaccines, aiming to stimulate the body's immune system to recognize and eliminate cancer cells. Additionally, MAGEA12 serves as a model for studying the broader implications of cancer-testis antigens in tumor biology and immune regulation. Investigating MAGEA12 recombinant protein can contribute to the development of personalized cancer treatments and improve outcomes by harnessing the body’s immune response. As ongoing research continues to elucidate its mechanisms and interactions within the immune system, MAGEA12 remains a promising focus area in the landscape of cancer research aimed at enhancing patient-specific therapeutic strategies.
